Trial Profile
An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Atorvastatin; Colestyramine; Ezetimibe; Fenofibrate; Fluvastatin; Lovastatin; Nicotinic acids; Omega-3-fatty-acid; Pravastatin; Rosuvastatin; Simvastatin
- Indications Hyperlipoproteinaemia type IIa
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi
- 01 Dec 2022 Results published in the Arteriosclerosis Thrombosis and Vascular Biology
- 17 May 2021 Results evaluating efficacy and safety of alirocumab in pediatric patients with Homozygous Familial Hypercholesterolemia presented at the 70th Annual Scientific Session of the American College of Cardiology
- 06 Aug 2020 This trial has been discontinued in Bulgaria according to European Clinical Trials Database record.